Global Insomnia Pharmacological Treatment Market Size was valued at USD 3.9 Billion in 2024 and is predicted to reach USD 7.3 Billion by 2034 at a 6.6% CAGR during the forecast period for 2025-2034.
Insomnia pharmacological treatment disorder can be caused by a variety of factors, including hectic schedules, emotional disorders, and other medical ailments. The greater need for prescription-based treatments and an increase in diagnosis are the results of increased knowledge of the long-lasting medical hazards associated with chronic insomnia. Additionally, the approach to which insomnia is treated is changing because of the increasing tendency regarding personalized healthcare and biomarker-based therapy.
The need for acceptable, non-habit-forming remedies, such as insomnia treatments based on melatonin, is driving the development of new products. Sublingual administration capsules and transdermal patches for skin represent several leading-edge medication delivery system advancements that are increasing treatment choices to accommodate a range of patient demands. Research institutes and pharmaceutical firms are collaborating strategically to speed up the development of tailored, non-sedative medicines, which will help the market grow.
However, the primary hurdle to the global market for pharmaceutical treatments for insomnia is the growing demand for non-pharmacological options. Consumers are becoming more health conscious about the possible dangers of long-term pharmaceutical use. Natural sleeping pills like a tea containing valerian base and melatonin are popular and may be purchased without a prescription. As a result of the wellness industry's advocacy of relaxation methods, meditation, and good sleep hygiene, the need for prescription sleep aids has decreased. Healthcare professionals are being taught to recommend psychological and lifestyle changes before thinking about using pharmaceutical therapies. The biggest obstacle to the development of the market for pharmaceutical treatments for insomnia is the potential drop in demand for these medications as knowledge and use of alternative treatments increase.
Competitive Landscape
Some of the Major Key Players in the Insomnia Pharmacological Treatment Market are
- Merck & Co Inc
- Ebb Therapeutics Inc/US
- Pfizer Inc
- Sanofi SA
- Takeda Pharmaceutical Co Ltd
- Paratek Pharmaceuticals Inc
- Electromedical Products International Inc
- Meda Pharmaceuticals Inc
- Purdue Pharma LP
- Pernix Therapeutics Holdings Inc
Market Segmentation:
The insomnia pharmacological treatment market is segmented based on drug, treatment, and distribution channel. Based on the drug, the market is segmented into OTC drugs, OTC sleep aids, OTC sleep supplements, and prescription drugs. By treatment, the market is segmented into over-the-counter sleep aids and prescription sleep aids. By distribution channel, the market is segmented into drug stores, e-commerce, hospital pharmacies, and retail pharmacies.
Based on the Treatment, the Prescription Sleep Aids Segment is Accounted as a Major Contributor to the Insomnia Pharmacological Treatment Market
Prescription sleep aids are expected to hold a significant global market share in 2024. The insomnia pharmacological treatment market because they are more effective and widely used to treat severe and chronic sleep problems. Advances in physiology have also contributed to the supremacy of prescription sleep aids by creating safer, better compositions with fewer adverse reactions and a lower probability of reliance. Demand has also increased due to growing consumer recognition of the need to obtain medical treatment for persistent insomnia and an increase in physician prescriptions. Numerous prescription sleep aids have been approved by regulators, increasing treatment alternatives and bolstering the sector's strength.
Hospital Pharmacies Segment to Witness Growth at a Rapid Rate
The hospital pharmacies segment is growing in the insomnia pharmacological treatment market because they play a crucial part in giving patients under medical surveillance the appropriate medications for insomnia. Strict regulations guaranteeing the safe administration of pharmacological sleep aids under professional oversight contribute to hospital pharmacies' popularity.
North American Insomnia Pharmacological Treatment Market Holds a Significant Revenue Share
The North American insomnia pharmacological treatment market is expected to register the highest market share in revenue in the near future. This can be attributed to the growing number of sleep-related illnesses in the US, which is driving up the need for insomnia-related treatments. Additionally, federal assistance in financing the medical management of insomnia is anticipated to be crucial to the growth of the pharmaceutical sector. In addition, the Asia Pacific is expected to grow rapidly in the insomnia pharmacological treatment market due to the region's widely recognized medical system, including insomnia clinics, the surge in the frequency of insomnia, and the high anxiety associated with the workplace. Furthermore, the industry is experiencing unheard-of growth due to nations adopting more sophisticated sleep technology.
Recent Developments:
- In January 2025, Pfizer Inc. announced that EMBLAVEO (aztreonam-avibactam) has been approved for the treatment of adult patients with complex intra-abdominal infections (cIAI) and illnesses (HAP), such as ventilator-associated pneumonia (VAP) and pyelonephritis (cUTI). It is also advised for the medical management of infections caused by aerobic Gram-negative germs in adults who have exhausted all other treatment choices.
- In December 2024, Takeda declared that the Japanese Ministry of Welfare, Labor, and Health (MHLW) accepted INTENSITY (maribavir) for the treatment of post-transplant CMV (cytomegalovirus) disorder or infection that is resistant to current anti-CMV medicines. INTENSITY is the sole and initial post-transplant anti-CMV medication authorized in Japan. It focuses on and restricts the pUL97 enzyme and its organic mediators.
Insomnia Pharmacological Treatment Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 3.9 Billion |
|
Revenue Forecast In 2034 |
USD 7.3 Billion |
|
Growth Rate CAGR |
CAGR of 6.6% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug, By Treatment, By Distribution Channel, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Merck & Co Inc, Ebb Therapeutics Inc/US, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Co Ltd, Paratek Pharmaceuticals Inc, Electromedical Products International Inc, Meda Pharmaceuticals Inc, Purdue Pharma LP, and Pernix Therapeutics Holdings Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
